GlassScriptPhysician profile
Thomas Bales
NPI 1649766114
$27,990.68
in general payments reported to CMS, 2019-2025
32 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,725 · 2022: $3,998 · 2023: $3,515 · 2024: $1,380 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $3,756 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,500.00 |
| Food and Beverage | $3,756.05 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $12,367.41 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $4,663.96 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,716.06 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,446.45 | 2021-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,384.04 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,050.57 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $775.89 | 2021-2024 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $754.00 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $705.69 | 2021-2024 | Austedo, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $694.65 | 2021-2024 | Rexulti |
| Lundbeck LLC | $498.05 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $331.43 | 2021-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $226.73 | 2021-2023 | Trintellix |
| Noven Therapeutics, LLC | $158.19 | 2021-2023 | Xelstrym |
| Indivior INC. | $147.07 | 2021-2025 | Perseris, Sublocade |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $146.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $144.41 | 2022 | |
| Ironshore Pharmaceuticals INC. | $130.72 | 2021-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $112.44 | 2022-2024 | Auvelity |
| Owp Pharmaceuticals, INC. | $111.45 | 2022-2024 | Subvenite, Lamotrigine |
| Alfasigma USA, INC. | $104.24 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $50.22 | 2021 | |
| Noven Pharmaceuticals, INC. | $39.25 | 2021 | |
| Uswm, LLC | $37.32 | 2021 | |
| Corium, LLC | $36.98 | 2023 | Azstarys |
| Eisai INC. | $29.66 | 2021-2022 | |
| Biogen, INC. | $28.65 | 2021-2023 | |
| Almatica Pharma LLC | $26.19 | 2024 | Loreev Xr |
| Masimo Corporation | $22.38 | 2023 | Emma and Isa |
| Livanova USA, INC. | $19.38 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.12 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $14.84 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.